Literature DB >> 1394759

Perioperative haemotherapy: I. Indications for blood component transfusion.

E T Crosby1.   

Abstract

The practice of transfusion medicine has undergone substantial change over the last decade. Much of the impetus for the change has come from the isolation of human immunodeficiency virus (HIV) and the linkage of HIV transmission to blood transfusion. The purpose of this paper is to collate and review the literature relating to the indications for blood transfusion and provide recommendations for the appropriate utilization of blood products. Peer-reviewed and published studies and reviews relating to aspects of clinical blood transfusion were identified through computer searches and searching of the bibliographies of identified articles. Emphasis was placed on the literature published within the last decade and particularly in the years 1985-91. Material was chosen which was of proved clinical importance and in which findings were consistent among different investigators or different centres. Less emphasis was placed on material reporting new findings of uncertain clinical relevance or findings that were not consistent with majority reports. It is concluded that the only indication for red cell transfusion is to increase the oxygen carrying capacity of the blood and that an adjustment downwards in the haemoglobin concentration at which blood is transfused (transfusion trigger) from the traditional level of 100 g.L-1 is supported by the physiological and clinical data. Perioperative haemoglobin concentrations of 80 g.L-1 are acceptable in otherwise healthy young patients. The transfusion trigger should be adjusted upwards from this in medically compromised patients and in the elderly (greater than 60 yr). Fresh frozen plasma (FFP) is only indicated when there are documented deficiencies of coagulation factors. Platelet concentrates (PC) are indicated for the treatment of clinical coagulopathy resulting from thrombocytopaenia or platelet dysfunction. Routine or prophylactic administration of either FFP or PC after cardiopulmonary bypass or during resuscitation from haemorrhage is not indicated.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1394759     DOI: 10.1007/BF03008233

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  67 in total

1.  The effect on blood coagulation of the exclusive use of transfusions of frozen red cells during and after cardiopulmonary bypass.

Authors:  J Umlas; R Sakhuja
Journal:  J Thorac Cardiovasc Surg       Date:  1975-09       Impact factor: 5.209

2.  Changing patterns of blood transfusions in four sets of United States hospitals, 1980 to 1985.

Authors:  D M Surgenor; E L Wallace; S G Hale; M W Gilpatrick
Journal:  Transfusion       Date:  1988 Nov-Dec       Impact factor: 3.157

Review 3.  A critical reappraisal of the bleeding time.

Authors:  R P Rodgers; J Levin
Journal:  Semin Thromb Hemost       Date:  1990-01       Impact factor: 4.180

Review 4.  New transfusion practice and haemostasis.

Authors:  G Myllylä
Journal:  Acta Anaesthesiol Scand Suppl       Date:  1988

5.  Haemostatic disorders in massive transfusion.

Authors:  H Harke; S Rahman
Journal:  Bibl Haematol       Date:  1980

6.  Graded coronary stenosis and coronary flow during acute normovolemic anemia.

Authors:  A S Geha; A E Baue
Journal:  World J Surg       Date:  1978-09       Impact factor: 3.352

7.  Acute normovolemic hemodilution. Changes of central hemodynamics and microcirculatory flow in skeletal muscle.

Authors:  K Messmer; D H Lewis; L Sunder-Plassmann; W P Klövekorn; N Mendler; K Holper
Journal:  Eur Surg Res       Date:  1972       Impact factor: 1.745

8.  Limitations of blood conservation.

Authors:  R D Weisel; D C Charlesworth; L L Mickleborough; S E Fremes; J Ivanov; D A Mickle; S J Teasdale; M F Glynn; H E Scully; B S Goldman
Journal:  J Thorac Cardiovasc Surg       Date:  1984-07       Impact factor: 5.209

9.  Characterization of biochemical changes occurring during storage of red cells. Comparative studies with CPD and CPDA-1 anticoagulant-preservative solutions.

Authors:  G Moroff; D Dende
Journal:  Transfusion       Date:  1983 Nov-Dec       Impact factor: 3.157

10.  Red cell substitutes: hemoglobin solution or fluorocarbon?

Authors:  S A Gould; A L Rosen; L R Sehgal; H L Sehgal; C L Rice; G S Moss
Journal:  J Trauma       Date:  1982-09
View more
  4 in total

Review 1.  Anesthesiological and intensive care considerations in children undergoing extensive cerebral excision procedure for congenital epileptogenic lesions.

Authors:  D Pietrini; F Zanghi; A Pusateri; F Tosi; S Pulitanò; M Piastra
Journal:  Childs Nerv Syst       Date:  2006-06-29       Impact factor: 1.475

2.  Changes in transfusion practice over time in the PICU.

Authors:  Michael D Dallman; Xinggang Liu; Anthony D Harris; John R Hess; Bennett B Edelman; David J Murphy; Giora Netzer
Journal:  Pediatr Crit Care Med       Date:  2013-11       Impact factor: 3.624

3.  Effects of colloidal resuscitation fluids on reticuloendothelial function and resistance to infection after hemorrhage.

Authors:  E A van Rijen; J J Ward; R A Little
Journal:  Clin Diagn Lab Immunol       Date:  1998-07

4.  Debate: transfusing to normal haemoglobin levels will not improve outcome.

Authors:  G Alvarez; P C Hébert; S Szick
Journal:  Crit Care       Date:  2001-03-08       Impact factor: 9.097

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.